Amgen Highlights Enbrel, Prolia and Amjevita Research at ACR 2016 Save

Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.

Amgen's products to be presented include etanercept (Amgen), denosumab (Prolia), the anti-sclerostin agent romosozumab (developed with UCB), and its new FDA approved biosimilar of adalimumab called ABP 501 or Amjevita (adalimumab-atto).

• Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study Abstract 2L, ACR Late-breaking Abstract Session, Tuesday, Nov. 15, 4:30 – 6 p.m. ET, Hall D
• Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension. Abstract 1028, ACR Concurrent Abstract Session, Sunday, Nov. 13, 4:30 – 6 p.m. ET, 145 A
• Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study.  Abstract 323, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall 
• The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab. Abstract 336, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
  Abstract 337, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis. Abstract 1023, ACR Concurrent Abstract Session, Sunday, Nov. 13, 4:30 – 6 p.m. ET, 145 A
• Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial. Abstract 1024, ACR Concurrent Abstract Session, Sunday, Nov. 13, 4:30 – 6 p.m. ET, 145 A.
• Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis. Abstract 321, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C.
• Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era.Abstract 526, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Abstract 591, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis. Abstract 592, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry. Abstract 1679, ACR Poster Session B, Monday, Nov. 14, 9 – 11 a.m. ET, Hall C
• Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis. Abstract 2231, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis. Abstract 2579, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)  Abstract 2233, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• The Longitudinal Impact of Biologic Use on Disability within a RA Registry. Abstract 2540, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis. Abstract 2172, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients. Abstract 2230, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry. Abstract 2605, ACR Poster Session C, Tuesday, Nov. 15, 9 – 11 a.m. ET, Hall C
• ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study. Abstract 616, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C
• Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects Abstract 615, ACR Poster Session A, Sunday, Nov. 13, 9 – 11 a.m. ET, Hall C